Condition

NSCLC (Non-small Cell Lung Carcinoma)

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11

Recruiting3

Common interventions18

Lead sponsors shown8

Clinical trials

11 shown

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaNCT07314216 · 2026-06-22

Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCNCT07050043 · 2025-05-19

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812 · 2026-12-01

NOT_YET_RECRUITING

Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLCNCT07842471 · 2026-10-08

NOT_YET_RECRUITING

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKINCT07551414 · 2026-05-30

NOT_YET_RECRUITING

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerNCT06685718 · 2024-12-05

A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaNCT02298153 · 2015-01-27

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsNCT02355431 · 2014-12-01

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerNCT02257619 · 2014-09-24

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerNCT02119650 · 2014-02-11

Common interventions

docetaxelDRUG2 ItacitinibDRUG2 placeboDRUG2 AtezolizumabDRUG1 BG-60366DRUG1 CisplatinDRUG1 Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, DocetaxelDRUG1 daraxonrasibDRUG1 Definitive Thoracic RadiotherapyRADIATION1 EpacadostatDRUG1 erlotinibDRUG1 FirmonertinibDRUG1 Immediate Local Consolidative Therapy (LCT)PROCEDURE1 Nivolumab 40mgDRUG1 PemetrexedDRUG1 RuxolitinibDRUG1 Signatera Genome ultra-sensitive ctDNA blood testDEVICE1 Zorifertinib Plus Intra-Ommaya CSF ChemotherapyDRUG1

Leading sponsors

Incyte Corporation 4 BeOne Medicines 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 Dr Arvindran A/L Alaga 1 Guangdong Provincial People's Hospital 1 Hunan Cancer Hospital 1 Natera, Inc. 1 Revolution Medicines, Inc. 1

Trial status mix

TERMINATED4

NOT_YET_RECRUITING3

RECRUITING3

WITHDRAWN1

Phase mix

PHASE26

PHASE12

PHASE32

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.